In vivo delivery of miRNAs for cancer therapy: challenges and strategies Y Chen, DY Gao, L Huang Advanced drug delivery reviews 81, 128-141, 2015 | 685 | 2015 |
Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy Y Chen, X Zhu, X Zhang, B Liu, L Huang Molecular therapy 18 (9), 1650-1656, 2010 | 668 | 2010 |
Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery J Li, YC Chen, YC Tseng, S Mozumdar, L Huang Journal of controlled release 142 (3), 416-421, 2010 | 545 | 2010 |
Role of SUMO-interacting motif in Daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors DY Lin, YS Huang, JC Jeng, HY Kuo, CC Chang, TT Chao, CC Ho, ... Molecular cell 24 (3), 341-354, 2006 | 522 | 2006 |
CXCR4 inhibition in tumor microenvironment facilitates anti‐programmed death receptor‐1 immunotherapy in sorafenib‐treated hepatocellular carcinoma in mice Y Chen, RR Ramjiawan, T Reiberger, MR Ng, T Hato, Y Huang, H Ochiai, ... Hepatology 61 (5), 1591-1602, 2015 | 441 | 2015 |
Tumor-targeted delivery of siRNA by self-assembled nanoparticles SD Li, YC Chen, MJ Hackett, L Huang Molecular Therapy 16 (1), 163-169, 2008 | 402 | 2008 |
Delivery of nitric oxide with a nanocarrier promotes tumour vessel normalization and potentiates anti-cancer therapies YC Sung, PR Jin, LA Chu, FF Hsu, MR Wang, CC Chang, SJ Chiou, ... Nature nanotechnology 14 (12), 1160-1169, 2019 | 333 | 2019 |
Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer Y Chen, SR Bathula, J Li, L Huang Journal of Biological Chemistry 285 (29), 22639-22650, 2010 | 260 | 2010 |
Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer KW Huang, FF Hsu, JT Qiu, GJ Chern, YA Lee, CC Chang, YT Huang, ... Science advances 6 (3), eaax5032, 2020 | 219 | 2020 |
Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal‐derived factor 1 alpha/C‐X‐C receptor type 4 axis and myeloid differentiation antigen … Y Chen, Y Huang, T Reiberger, AM Duyverman, P Huang, R Samuel, ... Hepatology 59 (4), 1435-1447, 2014 | 213 | 2014 |
Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy Y Chen, JJ Wu, L Huang Molecular therapy 18 (4), 828-834, 2010 | 203 | 2010 |
Targeted nanoparticles deliver siRNA to melanoma Y Chen, SR Bathula, Q Yang, L Huang Journal of Investigative Dermatology 130 (12), 2790-2798, 2010 | 140 | 2010 |
CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer DY Gao, TT Lin, YC Sung, YC Liu, WH Chiang, CC Chang, JY Liu, ... Biomaterials 67, 194-203, 2015 | 138 | 2015 |
Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy Y Chen, L Huang Expert opinion on drug delivery 5 (12), 1301-1311, 2008 | 137 | 2008 |
Quantum dot/antibody conjugates for in vivo cytometric imaging in mice HS Han, E Niemeyer, Y Huang, WS Kamoun, JD Martin, J Bhaumik, ... Proceedings of the National Academy of Sciences 112 (5), 1350-1355, 2015 | 136 | 2015 |
Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells Y Chen, J Sen, SR Bathula, Q Yang, R Fittipaldi, L Huang Molecular pharmaceutics 6 (3), 696-705, 2009 | 121 | 2009 |
An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis T Reiberger, Y Chen, RR Ramjiawan, T Hato, C Fan, R Samuel, ... Nature protocols 10 (8), 1264-1274, 2015 | 118 | 2015 |
Molecular mimicry of human endothelial cell antigen by autoantibodies to nonstructural protein 1 of dengue virus IJ Liu, CY Chiu, YC Chen, HC Wu Journal of Biological Chemistry 286 (11), 9726-9736, 2011 | 118 | 2011 |
Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis TT Lin, DY Gao, YC Liu, YC Sung, D Wan, JY Liu, T Chiang, L Wang, ... Journal of controlled release 221, 62-70, 2016 | 103 | 2016 |
Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development YC Sung, YC Liu, PH Chao, CC Chang, PR Jin, TT Lin, JA Lin, HT Cheng, ... Theranostics 8 (4), 894, 2018 | 91 | 2018 |